FDA under pressure to relax drug rules.

The article reports on the pressure on the U.S. Food and Drug Administration (FDA) to rethink its clinical-trial requirements for antibiotics as approval for antibiotics has been dropped with the proliferation of multi-drug resistant strains of bacteria in the U.S. It focuses on the strict clinical guidelines for antibiotics which have dogged the drug industry. However, Congress has passed measures encouraging drug development and FDA has pledged to reboot its antibiotic-approval process.